A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2/3
- Patients
- 690 (planned)
- Started
- Mar 13, 2026
- Main results expected
- Nov 8, 2030
- Fully finished
- Sep 11, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment
Measured over: Up to 2 years after the last participant is randomized
Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR)
Measured over: Up to approximately 33 months
Overall survival (OS)
Measured over: Up to approximately 47 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07221149 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC